CVS Caremark Expands Access to Eli Lilly’s Obesity Portfolio: Reinstates Zepbound, Adds Foundayo

FirstWord Pharma USA

Overview

CVS Caremark announced it will reinstate coverage for Eli Lilly’s injectable weight-loss medication Zepbound (tirzepatide) and add the newly launched oral GLP-1 drug Foundayo (orforglipron) to its standard commercial formularies. Effective June 1 for Foundayo and October 1 for Zepbound, this move significantly broadens patient access to Lilly’s robust obesity treatment portfolio. The decision positions Lilly on more equal competitive footing with Novo Nordisk across one of the largest pharmacy benefit managers in the U.S., intensifying market dynamics in the burgeoning obesity therapeutics sector.

In Depth

Background: The Competitive Landscape of Obesity Therapeutics and Access Challenges

The market for obesity pharmacotherapies has witnessed unprecedented growth, largely driven by the efficacy of GLP-1 receptor agonists. Eli Lilly’s Zepbound (tirzepatide) and Novo Nordisk’s Wegovy (semaglutide) are leading the charge, offering substantial weight loss benefits. However, widespread access to these high-cost medications has been a complex challenge, with pharmacy benefit managers (PBMs) playing a critical gatekeeping role in formulary coverage. Gaining preferred status on PBM formularies is paramount for market penetration and commercial success in this competitive space.

Key Findings / Results: CVS Caremark’s Strategic Formulary Update

• Reinstatement of Zepbound Coverage: CVS Caremark announced the reinstatement of Zepbound, Eli Lilly’s injectable GLP-1/GIP dual agonist, to its standard commercial formularies, effective October 1, 2026. This decision is significant as Zepbound had faced varying coverage restrictions on certain plans within CVS Caremark’s extensive network. Its reintroduction ensures broader access for eligible patients.
• Addition of Oral Foundayo: Concurrently, CVS Caremark will add Eli Lilly’s recently launched oral GLP-1 agonist, Foundayo (orforglipron), to its standard commercial formularies, effective June 1, 2026. Foundayo offers a convenient oral administration route, addressing a critical patient preference and potentially expanding the market to individuals who are hesitant or unable to use injectable medications.
• Competitive Realignment: This formulary update places Eli Lilly’s obesity portfolio in a more competitive position relative to Novo Nordisk within one of the largest PBMs in the United States. Historically, Novo Nordisk’s Wegovy often held a more favorable formulary position with CVS Caremark. The new coverage terms create a more level playing field, intensifying the competition for market share in the rapidly expanding obesity therapeutic segment.

Technical Significance & Outlook: Broadened Patient Access and Market Dynamics

CVS Caremark’s decision has profound technical and market implications. Firstly, it represents a substantial expansion of patient access to highly effective obesity treatments, potentially impacting millions of individuals grappling with obesity and its associated comorbidities. The availability of both injectable (Zepbound) and oral (Foundayo) options from a single manufacturer, with comprehensive PBM coverage, offers physicians and patients greater flexibility and choice in treatment approaches. Secondly, this move is expected to significantly bolster sales for Eli Lilly’s obesity franchise, strengthening its market leadership. From a broader industry perspective, the increased competition between pharmaceutical giants, driven by PBM formulary strategies, will likely spur further innovation in metabolic disease treatments, potentially leading to more potent, safer, and more convenient drug delivery systems. However, ongoing discussions around drug pricing and the financial sustainability of expanding access to these high-cost therapies will remain a critical aspect of healthcare policy and market evolution.